A phase 2 clinical investigation to determine the effects of the anti-oxidant bardoxolone on GFR in diabetic chronic kidney disease patients.


Estimated Time to View: 35 minutes
Title: Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Citation: The New England Journal of Medicine, 2011, June 24.
Date Created: 2011
Revisions: None Indicated
Disclaimers: Reata Pharmaceuticals (see page 9)
Resource Type: Video

Recommend to a Colleague/Friend



To view the interactive video, click here
To view this video using an iPad or iPhone, see below

Transparent Peer Review

GD Star Rating

To learn more about our 6-point transparent peer review system, click here

Bardoxolone in Chronic Kidney Disease -- The BEAM Trial, 9.2 out of 10 based on 1 rating


More in CKD, General Nephrology (40 of 212 articles)